528 related articles for article (PubMed ID: 16758264)
1. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Clark DW; Strandell J
Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
[TBL] [Abstract][Full Text] [Related]
2. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
3. A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database.
Sun Y; Zhang A; Zuo M; Chen J; Zhu L
J Gastroenterol Hepatol; 2024 Feb; 39(2):289-296. PubMed ID: 37961012
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitors: Risk for Myopathy?
Colmenares EW; Pappas AL
Ann Pharmacother; 2017 Jan; 51(1):66-71. PubMed ID: 27539734
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
7. Association Between Proton Pump Inhibitors and Microscopic Colitis.
Law EH; Badowski M; Hung YT; Weems K; Sanchez A; Lee TA
Ann Pharmacother; 2017 Mar; 51(3):253-263. PubMed ID: 27733667
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions.
Salgueiro E; Rubio T; Hidalgo A; Manso G
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):548-56. PubMed ID: 17176621
[TBL] [Abstract][Full Text] [Related]
9. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
Eur J Intern Med; 2019 Jan; 59():65-69. PubMed ID: 30154038
[TBL] [Abstract][Full Text] [Related]
10. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Kromer W
Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous reactions to proton pump inhibitors: a case-control study.
Chularojanamontri L; Jiamton S; Manapajon A; Suvanasuthi S; Kulthanan K; Dhana N; Jongjarearnprasert K
J Drugs Dermatol; 2012 Oct; 11(10):e43-7. PubMed ID: 23134998
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
[TBL] [Abstract][Full Text] [Related]
14. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
17. Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.
Capogrosso Sansone A; Convertino I; Galiulo MT; Salvadori S; Pieroni S; Knezevic T; Mantarro S; Marino A; Hauben M; Blandizzi C; Tuccori M
Drug Saf; 2017 Oct; 40(10):895-909. PubMed ID: 28681266
[TBL] [Abstract][Full Text] [Related]
18. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
19. [Study of cross reactivity between proton pump inhibitors].
Hammami S; Affes H; Ksouda K; Feki M; Sahnoun Z; Zeghal KM
Therapie; 2013; 68(6):361-8. PubMed ID: 24356187
[TBL] [Abstract][Full Text] [Related]
20. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Mullner K; Molnar B; Tulassay Z
Orv Hetil; 2007 Mar; 148(12):543-51. PubMed ID: 17444020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
